Lung Injury
Damage to any compartment of the lung caused by physical, chemical, or biological agents which characteristically elicit inflammatory reaction. These inflammatory reactions can either be acute and dominated by NEUTROPHILS, or chronic and dominated by LYMPHOCYTES and MACROPHAGES.
Subtype terms (5)
More specific conditions that are subtypes of Lung Injury in the MeSH hierarchy.
- Acute Lung Injury
72 drugs (46 approved, 26 experimental)
- Meconium Aspiration Syndrome
8 drugs (3 approved, 5 experimental)
- Pneumoconiosis
3 drugs (1 approved, 2 experimental)
- Radiation Pneumonitis
22 drugs (13 approved, 9 experimental)
- Ventilator-Induced Lung Injury
4 drugs approved
Drugs by status
Approved for this indication (1)
Phase 3 trials (2)
Phase 2 trials (2)
Phase 1 trials (1)
Organizations
Organization Involved with Phase 4 Indications (12)
Organization Involved with Phase 3 Indications (21)
- Asklepion
- Alexion
- Chimerix
- Mallinckrodt
- NeuroRx, Inc.
- Duke University
- Emory University
- Johns Hopkins University
- University of Tennessee
- University of Virginia
- University of California, San Diego
- University of California, San Francisco
- Vanderbilt University
- Karolinska Institute
- Pennsylvania State University
- University of Barcelona
- Catholic University of Sacred Heart, Rome
- The Swedish Research Council
- Blekinge County Council Hospital
- Leo Pharma
- JK Biostatistics AB
Organization Involved with Phase 2 Indications (65)
- Theravance
- Eli Lilly
- Genentech
- Aevi Genomic Medicine
- Faron Pharmaceuticals Ltd
- GlaxoSmithKline
- Hope Pharmaceuticals
- S-Evans Biosciences Co.,Ltd.
- Windtree Therapeutics
- Apeptico Forschung und Entwicklung GmbH
- National Institutes of Health (NIH)
- National Cancer Center, Korea
- National Cancer Institute (NCI)
- National Center for Research Resources (NCRR)
- Associação Fundo de Incentivo à Pesquisa
- Alexandria University
- Changhai Hospital
- University of London
- Damanhour University
- Harvard University
- University of Washington
- Oregon Health and Science University
- Queen's University, Belfast
- Rio de Janeiro State University
- Stanford University
- University of Edinburgh
- University of Manchester
- University of Michigan
- University of Milan
- Virginia Commonwealth University
- +35 more
Organization Involved with Phase 1 Indications (16)
- Actelion
- Tanox
- Parexel
- Northern State Medical University
- University of Kentucky
- University of Oklahoma
- University of Toronto
- University of Colorado, Denver
- Kafrelsheikh University
- Tsinghua University
- University of Colorado
- Northern Norway Regional Health Authority
- Exvastat Ltd.
- Viela Bio
- General Organization of Export and Import control system
- ReAlta Life Sciences, Inc.
Organization Involved with Other Experimental Indications (14)
- Merck
- Central South University
- Inonu University
- Instituto Nacional de Cardiologia Ignacio Chavez
- Mahidol University
- Nanjing Medical University
- University of Louisville
- Yokohama City University
- Peking University
- National Taiwan University
- University of Sao Paulo
- Free University of Brussels
- Shantou University
- University of Geneva